Market Movers: Clean Harbors (NYSE:CLH), DryShips (NASDAQ:DRYS), Avago Technologies Limited (NASDAQ:AVGO), bluebird bio (NASDAQ:BLUE), Oramed Pharmaceuticals Inc. (NASDAQ:ORMP


Clean Harbors, Inc. (NYSE:CLH) announced Revenues for the fourth quarter were $845.0 million, compared with $879.4 million in the same period of 2013. Income from operations in the fourth quarter of 2014 was $57.5 million, compared with $58.9 million in the same period of 2013. On Wednesday shares of Clean Harbors, Inc. (NYSE:CLH) closed at $56.00. Company’s sales growth for last 5 years was 27.80% and EPS growth for next 5 years is recorded as 12.00%.

DryShips, Inc. (NASDAQ:DRYS) recorded net loss of $24.0 million, or $0.04 basic and diluted loss per share, for the three-month period ended December 31, 2014, as compared to a net loss of $24.4 million, or $0.06 basic and diluted loss per share, for the three-month period ended December 31, 2013. Adjusted EBITDA was $298.7 million for the fourth quarter of 2014, as compared to $179.8 million for the same period in 2013. DryShips, Inc. (NASDAQ:DRYS) in last trading activity increased 4.08% to close at $1.02. Company weekly performance is 0.99% while its quarterly performance stands at -32.00%. DryShips, Inc. (NASDAQ:DRYS) is -75.05% away from its 52 week high.

Avago Technologies Limited (NASDAQ: AVGO) and Emulex Corporation (NYSE: ELX) announced that they have entered into a definitive agreement under which Avago will acquire Emulex, a leader in network connectivity, monitoring and management, in an all-cash transaction valued at approximately $606 million, or $609 million net of cash and debt acquired. On last trading day Avago Technologies Limited (NASDAQ:AVGO) moved down -0.44% to close at $112.68. Its volatility for the week is 1.44% while volatility for the month is 2.47%. AVGO’s sales growth for past 5 years was 23.50% and its EPS growth for past 5 years was 50.80%. Avago Technologies Limited (NASDAQ:AVGO) monthly performance is 5.57%.

bluebird bio, Inc. (NASDAQ:BLUE) reported fourth-quarter net loss of $19.5 million, or $0.67 a share, compared with a year-earlier loss of $8.1 million, or $0.34 a share. Revenue of $6.3 million for the recent period was unchanged from a year earlier. Wall Street expected a loss of $0.57 a share, on revenue of $6.18 million. bluebird bio, Inc. (NASDAQ:BLUE) has 1.10% insider ownership while its institutional ownership stands at 66.40%. In last trading activity company’s stock closed at $96.30.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that a scientific abstract titled “Protease Inhibitor Support in Oral Insulin Delivery” will be presented in poster sessions at the GTC Protease Inhibitors in Drug Discovery Conference on February 26-27, 2015 in San Diego.On last trading day Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) moved down -2.65% to close at $4.40. Its volatility for the week is 5.38% while volatility for the month is 5.34%. ORMP’s EPS growth for past 5 years was -1.30%. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) monthly performance is -10.57%.


Leave a Reply

Your email address will not be published. Required fields are marked *